Cosmos Health Inc. Stock Price, News & Analysis

Cosmos Holdings (NASDAQ: COSM) announces the commercial launch of its Sky Premium Life nutraceutical products on Amazon in the U.S., following successful market entries in Canada, the U.K., and Singapore. The company plans to introduce 15 SKUs in the third quarter of 2022 and aims for all 85 SKUs available by year-end. The U.S. nutraceutical market is projected to grow at a 7.1% CAGR, reaching $138.0 billion by 2027, driven by health-conscious consumer trends. CEO Greg Siokas emphasizes the significant demand for high-quality supplements.

Cosmos Holdings (NASDAQ: COSM) reported strong financial results for Q1 2022, with revenue increasing by 12.5% to $13.1 million and gross profit soaring 88.9% to $1.89 million. The company achieved a net income of $0.2 million and EBITDA of $1.2 million. Growth was driven by a 49.2% increase in sales of its proprietary nutritional supplements. Operating expenses were reduced by nearly 40%, enhancing profitability. The company aims to expand its nutraceutical portfolio and geographic reach, launching products in Amazon Singapore and Canada.

Cosmos Holdings (Nasdaq: COSM) announced the launch of its Sky Premium Life nutraceutical products on Amazon Canada. This initiative, facilitated by its subsidiary, SkyPharm S.A., will introduce 22 stock-keeping units (SKUs) in Q2 2022, aiming for a total of 85 SKUs by year-end. The North American nutraceutical market, valued at $88.3 billion in 2021, is expected to reach $118.73 billion by 2026, driven by heightened health awareness and demand for supplements during the COVID-19 pandemic.

Cosmos Holdings (NASDAQ:COSM) announced the appointment of Dr. Anastasios Aslidis to its Board of Directors and audit committee. Dr. Aslidis, a finance expert with over 30 years in the maritime industry, currently serves as CFO for EuroDry and Euroseas. His extensive experience in corporate finance is expected to aid Cosmos in scaling its operations and expanding its international presence. CEO Greg Siokas expressed confidence in Dr. Aslidis's background, emphasizing its alignment with the company's growth strategy in the nutraceutical and pharmaceutical markets.

Cosmos Holdings (NASDAQ:COSM) reported revenue growth for 2021, achieving $56.2 million, up from $55.4 million in 2020. The company also recorded positive adjusted net income of $383,747 and adjusted EBITDA of $3.3 million. Cosmos continues to expand its product line and distribution network, with new premium nutraceuticals launched and growth into new markets including Asia and Europe. The company uplisted to NASDAQ in early 2022 and focuses on reducing debt, increasing working capital by 69% to $11 million.

Cosmos Holdings (NASDAQ:COSM) has announced the launch of Mediterranation, a premium line of nutritional supplements under its Sky Premium Life brand. This line utilizes organic herbs and plant extracts sourced from Greece and the Mediterranean, featuring ingredients known for their health benefits, including polyphenols with antioxidant properties. CEO Greg Siokas highlighted the anticipated demand for these high-quality supplements and the company's growth strategy to expand into new global markets. Manufacturing adheres to strict pharmaceutical standards, ensuring quality.

Cosmos Holdings (NASDAQ:COSM) announced the launch of its Sky Premium Life products on Amazon Singapore, achieving the rollout ahead of schedule, with plans for 15 SKUs initially and 85 SKUs by year-end. This move comes as the Singapore e-commerce market is expected to grow from $5.9 billion in 2021 to $10.7 billion by 2025, driven by increasing online shopping preferences.

CEO Greg Siokas emphasized the significance of this launch in expanding their global market strategy amidst rising demand for nutraceuticals.

Cosmos Holdings (NASDAQ:COSM) has launched Brainlit, a new brain health supplement under its luxury line, Sky Premium Life. This product aims to address rising brain-related conditions like Alzheimer's, affecting over 55 million globally. The brain health supplement market is projected to grow from $7.7 billion in 2020 to $19.7 billion by 2030, driven by an aging population and increased demand for effective treatments. The formula includes key ingredients like ginkgo biloba, glutamine, and L-tyrosine, contributing to enhanced cognitive function.

Cosmos Holdings (Nasdaq: COSM) announces the launch of Prostatium, a proprietary supplement aimed at enhancing prostate health and preventing symptoms of Benign Prostate Hyperplasia (BPH). With about 30 million men affected worldwide, Prostatium includes proven ingredients like Saw Palmetto and Lycopene, manufactured under stringent standards. The company aims to expand its product reach across Europe and North America while tapping into the growing demand for high-quality nutraceuticals. CEO Greg Siokas highlighted the importance of this unique formulation developed by their R&D team.